NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
JSLL Empanels 44 Ayurveda Hospitals with Medsave Health Insurance TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has successfully empanelled 44 of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic arrangement enables the company to provide cashless Ayurvedic treatments to insured beneficiaries across a wide network of locations. The empanelment covers major Indian cities including Mumbai, Delhi, Bangalore, Hyderabad, and Kolkata, significantly enhancing service accessibility. This move is expected to drive higher patient footfall and revenue by integrating traditional treatments with mainstream insurance coverage.
முக்கிய அம்சங்கள்
Empanelment of 44 Ayurveda Panchkarma Hospital locations across India with Medsave Health Insurance TPA.Authorization to provide cashless treatment to insured beneficiaries under policies administered by Medsave.Geographical footprint spans major hubs including Navi Mumbai, Bangalore, Ahmedabad, Pune, and Lucknow.The arrangement is conducted in the ordinary course of business without any related party transactions.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of this empanelment on patient volumes and revenue growth in the upcoming quarters as insurance-backed Ayurvedic care gains traction. This development strengthens the company's competitive position in the organized wellness and healthcare sector.
Jeena Sikho Lifecare Appoints Forvis Mazars LLP as Internal Auditor Following Resignation
Jeena Sikho Lifecare Limited (JSLL) has announced a change in its internal audit function effective December 23, 2025. The company accepted the resignation of M/s Deepak K Garg & Associates, who cited pre-occupation with other professional commitments as the reason for leaving. In their place, the Board has appointed M/s Forvis Mazars LLP, a leading international assurance and advisory firm, for the financial year 2025-26. This transition to a global firm is typically seen as a move to strengthen internal controls and corporate governance.
முக்கிய அம்சங்கள்
Resignation of M/s Deepak K Garg & Associates as Internal Auditor effective December 23, 2025.Appointment of M/s Forvis Mazars LLP as the new Internal Auditor for the FY 2025-26 period.Outgoing auditor confirmed no material reasons for resignation other than professional commitments.The Board meeting for approval was held on December 23, 2025, concluding within 15 minutes.
👀 கவனிக்க வேண்டியவை
Investors should view the appointment of a globally recognized audit firm as a positive step for transparency and governance. No immediate portfolio action is required based on this routine management change.
JSLL Publishes 6 Medical Case Studies Validating Ayurvedic Treatment for Chronic Kidney Disease
Jeena Sikho Lifecare Limited (JSLL) has announced the publication of six case studies in medical journals such as the Academia Journal of Medicine and Advances in Applied Biological Research. These studies, co-authored by the company's Managing Director and medical experts, provide clinical evidence for Ayurvedic and Panchakarma interventions in managing Chronic Kidney Disease (CKD) and Diabetes. One specific case study reported a significant reduction in a patient's serum creatinine from 6.4 mg/dL to 3.55 mg/dL and urea from 142 mg/dL to 55.88 mg/dL. This move aims to strengthen the company's clinical credibility and promote evidence-based traditional healing.
முக்கிய அம்சங்கள்
Publication of 6 distinct case studies in peer-reviewed journals focusing on CKD and Diabetes management.Clinical data showed a patient's serum creatinine dropped from 6.4 mg/dL to 3.55 mg/dL over the treatment and follow-up period.Urea levels in the primary case study decreased from 142 mg/dL to 55.88 mg/dL, indicating significant renal function improvement.The research was co-authored by MD Acharya Manish Grover and a team of 8 medical professionals associated with the company.The studies highlight the integration of Panchakarma therapies, specific herbal formulations, and the 'DIP Diet' in clinical practice.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward clinical validation of the company's core service offerings, which may drive higher patient trust and footfall. Monitor if this research leads to wider institutional acceptance or expansion of their hospital network.
JSLL receives in-principle approval for ESOP listing of 2,50,000 shares
Jeena Sikho Lifecare Limited (JSLL) has received in-principle approval from both NSE and BSE for listing up to 2,50,000 equity shares of ₹2 each under the 'Jeena Sikho Employees Stock Option Scheme, 2025'. This regulatory filing indicates the company's progress in implementing its ESOP program. The approvals are subject to the company fulfilling various listing conditions and regulatory requirements. Investors should note that this is an in-principle approval and the actual listing is contingent on further compliances.
முக்கிய அம்சங்கள்
In-principle approval received for listing of up to 2,50,000 Equity Shares.Each equity share has a face value of ₹2.Approval granted under 'Jeena Sikho Employees Stock Option Scheme, 2025'.Approval received from National Stock Exchange of India Limited (NSE) vide Ref: NSE/LIST/51687 dated December 9, 2025.Approval received from BSE Limited vide Ref: DCS/ESOP/IP/RG/3955/2025-26 dated December 10, 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor JSLL's progress in fulfilling the listing conditions and keep an eye out for the actual listing date. This ESOP issuance could potentially dilute existing shareholders' equity, but the impact is likely to be minimal given the relatively small number of shares involved.
JSLL Clinical Success: HbA1c Drops from 9.3% to 6.4% in Peer-Reviewed Ayurvedic Case Study
Jeena Sikho Lifecare Limited (JSLL) has published three clinical case studies in the 'World Journal of Pharmaceutical and Life Sciences' to provide evidence-based validation for its Ayurvedic treatments. A primary study on Type 2 Diabetes showed a significant reduction in HbA1c from 9.3% to 6.4% and a drop in Random Blood Sugar from 265 mg/dL to 153 mg/dL. The publications, co-authored by the Managing Director and senior medical consultants, also cover treatments for Pancreatitis and Liver disorders. This move strengthens the company's scientific credibility in the alternative medicine space.
முக்கிய அம்சங்கள்
Published 3 case studies in the peer-reviewed 'World Journal of Pharmaceutical and Life Sciences' covering Diabetes, Pancreatitis, and Liver disorders.Diabetes case study reported a significant HbA1c reduction from 9.3% to 6.4% and average glucose drop from 220 mg/dL to 137 mg/dL.Patient weight improved from 59 kg to 62.6 kg during the treatment period from September 2024 to April 2025.Treatments utilized the company's proprietary 'DIP Diet' and personalized Ayurvedic protocols including Shodhana and Shamana.Studies were co-authored by MD Acharya Manish Grover and a team of six medical professionals associated with the company.
👀 கவனிக்க வேண்டியவை
Investors should recognize this as a positive step toward institutionalizing Ayurvedic practices through clinical evidence, which can enhance brand trust and patient acquisition. Monitor for further large-scale clinical trials that could provide deeper scientific moats for the company's services.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Jindal Stainless ranks among global top 5% in DJSI scores
Jindal Stainless has achieved an ESG score of 78 in the Dow Jones Sustainability Index (DJSI) Corporate Sustainability Assessment (CSA) for FY25, placing it among the top 5% of steel companies globally. The company ranks fourth in the steel sector and first in the stainless steel sector worldwide. Jindal Stainless' ESG scores are 83 in Environmental, 73 in Social, and 76 in Governance & Economic, exceeding the industry averages of 37, 35, and 36, respectively. The company also achieved a 14% year-on-year reduction in GHG emissions in FY25.
முக்கிய அம்சங்கள்
Jindal Stainless secured an ESG score of 78 in DJSI for FY25.The company ranks in the top 5% of steel companies globally.Jindal Stainless achieved Environmental score of 83, Social score of 73 and Governance & Economic score of 76.The company achieved a 14% year-on-year reduction in GHG emissions in FY25.Jindal Stainless had an annual turnover of INR 40,182 crore (USD 4.75 billion) in FY25.
👀 கவனிக்க வேண்டியவை
The improved ESG ranking is a positive signal. Investors should monitor the company's continued progress on its Vision 2030 ambitions and sustainability initiatives.
Jindal Stainless launches 'JSL Saathi Pragati' loyalty program
Jindal Stainless Limited (JSL) has launched 'JSL Saathi Pragati', a loyalty program for the stainless steel Pipes & Tubes segment. Over 30,000 fabricators and retailers are already onboarded. The program aims to ensure product authenticity and reward retailers and fabricators. JSL had an annual turnover of INR 40,182 crore (USD 4.75 billion) in FY25 and is ramping up its facilities to reach 4.2 million tonnes of annual melt capacity in FY27.
முக்கிய அம்சங்கள்
JSL had an annual turnover of INR 40,182 crore (USD 4.75 billion) in FY25Targeting 4.2 million tonnes of annual melt capacity in FY27Over 30,000 fabricators and retailers already onboardedJSL has 16 stainless steel manufacturing and processing facilities in India and abroad
👀 கவனிக்க வேண்டியவை
Investors should monitor the adoption rate of the 'JSL Saathi Pragati' program and its impact on sales and brand perception. Also, keep an eye on the company's progress towards achieving its 4.2 million tonnes capacity target by FY27.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
